CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®

CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®

Objective. Evaluation of pharmacokinetics, pharmacodynamics, safety and efficacy of rituximab biosimilar (Acellbia,  BIOCAD, Russia) used as  monotherapy in patients with indolent B-cell non-Hodgkin’s lymphoma in comparison with the parameters of innovator rituximab – MabThera.Materials and methods....

Full description

Saved in:
Bibliographic Details
Main Authors: S. M. Alekseev, K. D. Kaplanov, R. A. Ivanov, E. V. Chernyaeva
Format: Article
Language:Russian
Published: QUASAR, LLC 2015-04-01
Series:Исследования и практика в медицине
Subjects:
rituximab
biosimilar
acellbia®
non-hodgkin’ lymphoma
b-cell depletion
Online Access:https://www.rpmj.ru/rpmj/article/view/30
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items